爱普塔集团

最新新闻

• 评级变动
  DBS Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $170
  \u5e02\u573a\u8d44\u8baf · 2026/3/19
• 评级变动
  Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $145
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• 评级变动
  Wells Fargo Downgrades AptarGroup(ATR.US) to Hold Rating, Maintains Target Price $133
  \u5e02\u573a\u8d44\u8baf · 2026/1/6
• 公司公告
  AI: Statutory ex post facto disclosure documents (merger) (ATR-Trek Co., Ltd.)
  JPX · 2025/9/1
• 评级变动
  Raymond James Maintains AptarGroup(ATR.US) With Buy Rating, Cuts Target Price to $160
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  BofA Securities Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $173
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  BofA Securities Maintains AptarGroup(ATR.US) With Hold Rating, Announces Target Price $142
  \u5e02\u573a\u8d44\u8baf · 2026/1/5
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: AptarGroup (ATR) and Contineum Therapeutics, Inc. Class A (CTNM)
  TipRanks · 2026/7/31
• 公司公告
  AI: Statutory Advance Disclosure Documents (merger) (ATR-Trek Co., Ltd.)
  JPX · 2025/7/22
• Azitra, Inc. Advances ATR-04 Phase 1/2 Clinical Trial to Cohort 2 Following Safety Review Committee Clearance
  PR Newswire · 2026/10/1
• BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/1
• Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $155
  \u5e02\u573a\u8d44\u8baf · 2026/8/3
• BofA Securities Maintains AptarGroup(ATR.US) With Buy Rating, Maintains Target Price $172
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  Baird Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $156
  \u5e02\u573a\u8d44\u8baf · 2026/2/9
• 评级变动
  BofA Securities Maintains AptarGroup(ATR.US) With Hold Rating, Cuts Target Price to $145
  \u5e02\u573a\u8d44\u8baf · 2026/4/6
• 评级变动
  Wells Fargo Upgrades AptarGroup(ATR.US) to Buy Rating, Raises Target Price to $144
  \u5e02\u573a\u8d44\u8baf · 2026/3/20
• 评级变动
  Wells Fargo Maintains AptarGroup(ATR.US) With Buy Rating, Raises Target Price to $145
  \u5e02\u573a\u8d44\u8baf · 2026/5/4
• 评级变动
  BofA Securities Maintains AptarGroup(ATR.US) With Hold Rating, Maintains Target Price $147
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
  TipRanks · 2026/3/26
• William Blair Maintains AptarGroup(ATR.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。